Basket | Login | Register


Eleusis reports results from Phase I trial of LSD in older healthy participants

Wednesday 18 December 2019

The clinical stage life company Eleusis announced results from its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of low doses of lysergic acid diethylamide (LSD), a hallucinogenic drug, in older healthy participants.

The double-blind, placebo-controlled and randomised study was conducted in London. In this trial, 48 healthy participants (average age of 63 years old) received orally and repeated doses of LSD (5, 10 or 20 μg) every four days. Over a 3-week period of dosing, researchers monitored the participants’ health and the adverse events. Measures included clinical laboratory evaluations, physical and psychiatric health exams, blood pressure, heart rate, electrocardiogram, cognition and proprioception.

The company found that low doses of LSD were safe and well-tolerated, and it plans to support further clinical development of the drug for the treatment and prevention of Alzheimer’s disease. Findings were presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) conference and published in the journal Psychopharmacology. Scientists reported that it was the first clinical trial evaluating low doses of LSD.